InsidersTradesSigma
Follow the ブライトパス・バイオ株式会社 share price and the full insider trade history of the company, a publicly traded company based in Japan. Shares are quoted on the JP market, under the authority of EDINET (Japan FSA). Operating in the Health Care sector, ブライトパス・バイオ株式会社 has logged 31 reports. Market capitalisation: €6.9bn. The latest transaction was disclosed on 11 July 2025 (Holding update). Among the most active insiders: Evo Fund. All data is accessible without an account.
31
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
9Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,784 of 29,062 companies
26.5
score / 100
Value11
Quality42
FCF yld-20%
Earn yld-19%
EV/EBITDA·
ROE-79%
Gross mgn64%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 July 2025
Declarations31 total
ShareXTKSEDINET:S100U3ZE
1.0% of flowShareXTKSEDINET:S100U13R
2.6% of flowShareXTKSEDINET:S100T74Z
43.1% of flowShareXTKSEDINET:S100T1HQ
9.3% of flowShareXTKSEDINET:S100T0GW
6.3% of flowShareXTKSEDINET:S100SY98
3.9% of flowShareXTKSEDINET:S100SVH4
8.3% of flowShareXTKSEDINET:S100SP3A
25 of 31 declarations
Acerca de ブライトパス・バイオ株式会社
BrightPath Biotherapeutics es una empresa centrada en el sector de la salud y farmacéutico, dedicada al desarrollo de terapias innovadoras. Cotiza en el mercado XTKS.